Please assess the completion status of the following clinical trial:

Trial Title: Study of GDX012 in Patients With MRD Positive AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* Weight ≥ 40 kg~* Anticipated life expectancy \> 3 months prior to lymphodepletion~* Karnofsky Performance Score ≥ 70%~* Histologically confirmed diagnosis of AML~* In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted~* MRD detected in bone marrow by MFC~* Negative pregnancy test (females of childbearing potential only)~* Agree to use effective birth control~* Left ventricular ejection fraction (LVEF) ≥ 50%~* Platelet Count ≥ 20 x 109/L~* Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)~* Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)~* Hemoglobin ≥ 8.0 g/dL~* Creatinine Clearance ≥ 40mL/min~* Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin \< 35% of Total Bilirubin)~* ALT ≤ 2.5 x ULN~Exclusion Criteria:~* Cytotoxic chemotherapy within 3 weeks~* Immune therapy within 4 weeks~* Immunosuppressive therapy within 2 weeks (with exceptions)~* Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer~* Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities~* Known hypersensitivity to chemotherapy, other agents, or excipients used in this study~* Female patient that is pregnant or lactating/breastfeeding~* Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1 (with exceptions)~* History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents)~* Active CNS involvement (i.e. leukemic infiltration)~* Any other malignancy that requires active therapy~* Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months)~* Active infection with HIV, Hepatitis B or Hepatitis C~NOTE: other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDX012 Suspension for IV Infusion (Type: EXPERIMENTAL): Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells

Based on this trial design, predict the completion outcome and termination type (if applicable).